Evaluation reveals deep learning methods improve diagnostic understanding for Alzheimer’s disease, indicating trust in AI tools may rise.
Alzheimer’s disease (AD) is a neurodegenerative condition that gradually deteriorates memory and cognitive abilities, posing a significant global health challenge. While convolutional neural networks (CNNs) applied to structural magnetic resonance imaging (MRI) have achieved high diagnostic accuracy, their decision-making processes often lack transparency, which can limit clinical trust. This study presents a structured evaluation framework by applying multiple gradient-based and model-agnostic interpretability methods, such as Grad-CAM, Grad-CAM++, HiRes-CAM, Backpropagation, Guided Backpropagation, Kernel SHAP, LIME, and RISE, to pre-trained and custom CNN architectures for AD classification. We utilized the ADNI MRI dataset and assessed models based on accuracy, sensitivity, specificity, and visual alignment of highlighted brain regions with established biomarkers. By analyzing both predictive performance and explanation validity, this study aims to assist clinicians in making informed diagnoses, ultimately strengthening trust in AI-assisted tools.
No takes yet. Share an insight, caveat, or question.
Chakroborty et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: